Innovation
4 patent families (2 granted) — focus: Human necessities; filing pace accelerating.
Develops cytoprotective therapies for the treatment of end-stage renal disease (ESRD) and other diseases
4 patent families (2 granted) — focus: Human necessities; filing pace accelerating.